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Chapter 1 – Epidemiology, risk factors  
 
1.1 Epidemiology of Breast Cancer 
Breast cancer is the most common form of malignancy in women and since the incidence of 
the disease rises steeply with age, the number of breast cancer registrations worldwide 
continues to rise with the increasing age of the population.  In the UK nearly 50,000 new 
breast cancers in women are diagnosed each year and 12,000 will die of the disease, which 
is the second most common cause of death from cancer in women.  However almost 80% of 
women diagnosed with breast cancer will be alive 10 years later. The incidence of breast 
cancer rises sharply with age and the age-specific rate continues to rise indefinitely (Figure 
1). Furthermore the age-specific incidence rates continue to rise over time. This trend is 
probably related to demographic changes in the female population with an increase in many 
of the risk factors considered below. 
Average number of new cases of breast cancer per year and age-specific incidence rates per 
100,000 population.  Source: Cancer Research UK (2014)1  
Figure 1 - Breast Cancer incidence UK 2009-2011 
 
In the UK 20% of breast cancers in the UK were diagnosed in the NHS Breast Screening 
Programme which was opened in 1988 but this proportion has now risen to over 30%.  
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Breast screening is further considered in Chapter 3 but in common with most countries the 
introduction of breast cancer screening has led to an additional increase in incidence2.  
However although the number of deaths from breast cancer has risen commensurately with 
the incidence, Peto and colleagues3 were perhaps the first to point out that from the late 
1980’s breast cancer mortality in the UK and USA had fallen 25% by the year 2000.  They 
argued that the reason for this precipitous fall in mortality in both countries was likely to be 
multi-factorial but largely centred on the changes in the diagnosis and treatment of breast 
cancer. 
 
 
 
 from Peto et al (2000)3 
1.2 Risk factors for breast cancer  
The main risk factors for the development of breast cancer, apart from age and family 
history, concern the length of time that women are exposed to the effects of oestrogens.  
Five of the eight factors considered by the Million Women Study Collaborators4 are 
oestrogen related: age at menarche; parity; age at first birth; age at menopause and 
hormone replacement therapy.  The three other contributing factors are family history, 
alcohol consumption and Body Mass Index (BMI).  Excess weight is only a significant risk 
factor in postmenopausal women and paradoxically, height is a risk factor in young women5. 
Figure 2 - Breast cancer mortality per 100,000 population 1950-2000 UK and USA 
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Of the several other risk factors that have been considered, increased breast density on 
mammography6 is likely to be related to oestrogen exposure and benign breast disease is 
related to cellular atypia as in atypical ductal hyperplasia7.  Diet8-10, physical exercise11,12 and 
smoking12-14 have been extensively investigated but any attributable risks remain 
controversial. 
Ionising radiation is a known but now rare risk for the subsequent development of breast 
cancer, exemplified by radiological screening for pulmonary tuberculosis15 and mantle 
radiotherapy for Hodgkin’s disease16, especially in young women. Digoxin17 has recently 
been associated with an increased risk of breast cancer and metformin18 is known to have a 
protective effect. 
1.3 Ethnicity 
Breast Cancer is less common in Japan19 and in much of the developing world although 
there is a rising trend due to changes in life-style and life expectancy.  The incidence in Black 
and Asian women in the UK is lower than in the white population but this may be largely 
explained by differences in known risk factors rather than in true ethnic factors20.  
Nevertheless when women of non-white ethnicity develop breast cancer this tends to have 
a worse prognosis21-23.  
1.4 Clinical Management of Breast Cancer 
For a newly presenting patient with possible breast cancer the clinician will wish to establish 
a histological diagnosis by carrying out a core biopsy at an early stage in order that the 
recommendations for treatment can be considered by the Multi-Disciplinary Team (MDT) in 
a timely manner.  The clinician will then be in a better position to discuss the diagnosis, the 
outlook and the treatment options with the patient before any surgery is carried out. The 
MDT will normally be attended on a weekly or even twice weekly basis by an oncologist, a 
pathologist, a radiologist, a surgeon or breast physician, a breast specialist nurse and a data 
manager.  These specialists will all have a dedicated practice in breast cancer and where 
appropriate will have access to reconstructive surgery and genetic, psychological, geriatric 
and palliative care advice. The clinician will wish to establish the extent of the disease in the 
breast and axilla and if there is any suspicion, to exclude metastatic disease.  The histology 
will reveal the tumour type and grade, the oestrogen and progesterone receptor (ER/PR) 
and Human Epidermal Growth Factor Receptor 2 (Her2) receptor status. If the tumour is 
locally advanced or has particularly unfavourable features on histology such as a Triple 
Negative (ER/PR/Her2 -ve) tumour, this may lead the MDT to advise neoadjuvant therapy 
with chemotherapy. 
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1.5 Surgical options 
The axilla will usually be assessed by ultrasound examination and, if the nodes are 
suspicious of secondary disease, a needle or core biopsy will be taken.  The most 
appropriate management of the minimally node positive axilla is currently uncertain and 
this is further discussed in Section 4.15. Unless conservative surgery is contraindicated by a 
large or multifocal tumour, a wide local excision to clear margins will be advised with post-
operative radiotherapy.  There has been uncertainty as to what constitutes a ‘clear margin’ 
with some centres requiring 1cm between the tumour and the inked margin which many 
clinicians felt was excessive and which has resulted in re-excision rates of 20-25%. However 
there has recently been a definitive statement from The American Society of Clinical 
Oncologists (ASCO) which is a highly influential body worldwide, that no ink on the tumour 
(a minimal clearance) should be the new standard of care24, which will hopefully lead to a 
change in clinical practice.  If a mastectomy is indicated the patient should be offered a 
reconstruction, which can be immediate unless post-operative radiotherapy is likely.  There 
is concern that when radiotherapy is given after a breast reconstruction that the long-term 
cosmetic outcome is disadvantaged, especially when an implant has been inserted.  
Subsequent examination of the resected tumour will give further information such as the 
presence of lymphovascular invasion, the invasive tumour size and the resection margins.  
Increasingly genomic tests such as the 21 gene signature Oncotype DX25 or more recently a 
70 gene profile are being used to tailor adjuvant treatment by genomic profiling.  Adjuvant 
hormone therapy would normally be advised for ER+ve tumours, usually with an aromatase 
inhibitor26 or for Her 2 positive tumours with a monoclonal antibody, trastuzumab 
(Herceptin)27. The potential advantage of adjuvant chemotherapy will often be assessed 
with a prediction tool such as Adjuvant! Online, although this may not be accurate in older 
women28, or sometimes with Predict29 which is modelled on a population of patients in the 
UK. 
The difficulties of communicating this information and the alternative of primary endocrine 
therapy to an elderly woman in a holistic setting are not inconsiderable and are further 
considered in the Discussion section (5.10). 
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Chapter 2 – Tamoxifen in the older woman  
 
2.1 Introduction  
This chapter presents a brief historical perspective of the main treatment strategies for 
breast cancer. This chapter also presents two completed studies, a clinical trial with 
subsequent long-term follow-up which investigates the role of tamoxifen in older women 
with breast cancer, on outcomes of survival and quality of life. The contribution of these 
studies to the broader evidence base is considered.  
2.2 Hormone Therapy 
The first indication that the outcome of advanced breast cancer could be improved by 
hormone manipulation came from Beatson in 1896 who achieved an objective remission of 
locally advanced disease in three women from bilateral oophorectomy without knowledge 
of the endocrine mechanism30. However it was many years later that the value of ovarian 
ablation in the management of breast cancer was recognised.  The discovery of sex 
hormones led Haddow to give stilboestrol (an oestrogen) to women with advanced breast 
cancer31 and subsequently for the UK Christie group32 and the Scandinavian group33 in the 
1960’s to trial adjuvant ovarian ablation with radiotherapy in early breast cancer with 
limited success.  However the subsequent overview of all randomised trials of ovarian 
ablation34 by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) left no doubt as 
to the value of the intervention.  
2.3 Surgery 
The effective surgical treatment of early breast cancer only became a real option with the 
advent of general anaesthesia but it was William Halsted of Baltimore who pioneered 
radical mastectomy for the cure of the disease35.  However the disappointing late results of 
survival from his operations published in 1932 showed that few if any patients had actually 
been cured36.  At the same time as this publication, Geoffrey Keynes reported that 
conservative surgery for breast cancer with adjuvant radium needles showed similar 
outcomes to radical mastectomy, albeit from historical controls37,38.  Nevertheless radical 
mastectomy remained the accepted standard of care for many years until randomised trials 
of conservative surgery with adjuvant radiotherapy showed equivalent outcomes to radical 
surgery for early breast cancer39,40.  Historically, the surgical management of early breast 
cancer in older women was essentially the same as in younger women within the 
constraints of increasing comorbidities and fitness for anaesthesia.  
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2.4 Clinical Management 
Breast cancer is a multi-faceted disease and the outlook for patients depends on many 
factors so that the prognosis for survival, free of recurrent disease may vary between an 
essentially normal expectation of life seen with many screen-detected tumours, and an 
aggressive cancer which fails to respond to the best efforts of surgeons and oncologists.  
The management of breast cancer has changed over time with the advent and increasing 
use of adjuvant therapies and more conservative surgery41,42, which has substantially 
improved the outcome for patients43.  
The prognosis for recurrence-free survival from breast cancer may be substantially 
improved with the use of hormones and radiotherapy 41 and with chemotherapy42 but the 
extent of local44 and axillary disease45, the tumour size, grade, node status46 and hormone 
receptor status44 also affect the outcome as may the age of the patient and the presence of 
comorbid disease or obesity in older women47,48.  However the optimal clinical management 
of the patient is crucial to achieving the best outcome in any given clinico-pathological 
situation. 
2.5 Tamoxifen – early trials  
Tamoxifen is an anti-oestrogen, which was first synthesised and developed by ICI (now 
AstraZeneca) in the 1960’s.  The first clinical trial investigating survival in patients with 
advanced breast cancer at the Christie Hospital in 1971 was equivocal49  but a second trial in 
1973 was more successful at a higher dose50.  From this time onwards several studies of 
tamoxifen (Nolvadex) in various settings were carried out.  On the premise that breast 
cancer is often a systemic rather than a localised disease, a randomised controlled trial 
(RCT) was set up in 1977 of adjuvant tamoxifen for two years versus no further treatment, 
all patients having a mastectomy and axillary surgery.  This was a multicentre trial run by the 
Nolvadex Adjuvant Trial Organisation (NATO) and chaired by Michael Baum at King’s College 
Hospital.  My role in this trial was to enter all eligible patients from the Breast Clinic at 
Ashford Hospital Kent, from trial inception until closure in 198151.  By four years follow-up, 
this trial was already showing an overall survival benefit from adjuvant tamoxifen52 and at 
six years of follow-up the improvements in disease–free and overall survival were highly 
significant53. This early trial was conducted without knowledge of ER status and the known 
benefits were likely to have been underestimated.  
Subsequent trials have shown that five years of tamoxifen are superior to two years but that 
there is no benefit in patients who are ER negative.  A meta-analysis of published RCTs 
conducted by the EBCTCG54 found that five years of tamoxifen reduced breast cancer 
mortality by one third at up to 14 years follow-up.  As was common practice the NATO trial 
had an upper age limit of 75 years (although 70 years was more common), with the result 
that evidence from most RCTs cannot be extrapolated to older women with any confidence.  
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Postscript.  Tamoxifen is not a pure anti-oestrogen and does have an agonist effect on the 
endometrium, which leads to an excess of endometrial cancers although these are usually 
low-grade.  To some extent the use of tamoxifen has been overtaken by pure antagonists 
such as fulvestrant (Faslodex) and by the aromatase inhibitors such as anastrozole 
(Arimidex).  Nevertheless, its widespread use is generally considered to be responsible for 
much of the reduction in breast cancer mortality over the last 20 years.  
2.6 Primary Tamoxifen Therapy 
At about the same time that the NATO trial of adjuvant tamoxifen was set up several 
uncontrolled, non-randomised studies of tamoxifen as the sole primary treatment for 
operable breast cancer in older women were undertaken on the premise that frail elderly 
patients with significant morbidity might be spared an operation.  The results from these 
relatively small pilot studies showed that approximately one third of patients had a 
complete remission and a further one third had static disease.  All the reported studies gave 
a positive recommendation for use of primary tamoxifen therapy in elderly women55-59 with 
one exception60.  However, Bradbeer recommended that an accurate assessment of the role 
of tamoxifen in older women warranted investigation within a rigorous RCT57. 
2.7 Need for clinical trials  
There have been many changes in the management of breast cancer over the last forty 
years but the RCT was introduced to surgical practice at a relatively early stage51,61,62.  It 
gradually became accepted that for any change in current  clinical practice, evidence from 
rigorously conducted clinical trials should take precedence over guidance based on the 
consensus of expert opinion63.  
2.8 Study 1 (Appendix 1) 
Breast cancer in elderly women: a Cancer Research Campaign trial comparing 
treatment with tamoxifen and optimal surgery with tamoxifen alone. Bates 
T, Riley DL, Houghton J, Fallowfield L, Baum M.   Br J Surg 1991; 78: 591-4. 
It was in the above setting of uncertainty in the use of tamoxifen as a sole treatment 
strategy that three RCTs of primary tamoxifen therapy for operable breast cancer in older 
women were set up in the 1980’s in the UK, at St George’s, at Nottingham and the present 
multicentre Cancer Research Campaign (CRC)61 study centred at King’s College Hospital, 
London. 
The Trials at Nottingham64 and St George’s65 both compared surgery alone with tamoxifen 
alone but at about the same time, it was felt that there was an ethical difficulty in 
withholding tamoxifen from one group of patients in view of the mounting evidence of 
benefit from primary endocrine therapy.  As principal investigator and in collaboration with 
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Michael Baum at the CRC Unit, I therefore set up a multicentre RCT to compare tamoxifen 
alone with tamoxifen together with optimal surgery in women over the age of 70 with 
operable  breast cancer61.  
2.9 Interim Results 
An interim analysis of this trial was reported on 354 women61.  The extent of surgery was at 
the discretion of the individual surgeon and the majority of women (77%) had a wide local 
excision rather than mastectomy. Post-operative radiotherapy was not included in the 
protocol and although this led to a high local recurrence rate (17%) in those patients having 
breast conservation, in those randomised to tamoxifen-alone a change of management due 
to progressive disease was significantly more frequent. The results of this trial indicated that 
for the first change of management there was an excess of local treatment failure in the 
conservatively treated patients on tamoxifen alone compared with the surgically treated 
patients (n=64 vs. n=33).  This led to further surgery in 35 vs 15 patients respectively 
(p<0.001). Figure 1 of the published document in Appendix 1 shows that most changes of 
management occurred in the first 12 months from randomisation. 
2.10 Other key findings from Study 1 
Quality of Life Evaluation: Postoperative quality of life was assessed by the General Health 
Questionnaire 28 (GHQ-28) at one year after treatment.  There was no difference in the 
quality of life between the two arms in this trial.  
Tumour Response:  Of those patients receiving tamoxifen alone, the best ever tumour 
response was complete remission in one third and a partial remission or no change in 
almost two thirds. However 12% of patients in this group had tumour progression at six 
months and 6% at the best ever assessment. Ten patients in the surgically treated group did 
not undergo surgery, eight because they declined an operation post randomisation.  
Interim Conclusion: Analysis was by intention to treat61 and showed no difference in survival 
at three years. It was therefore concluded that there was no disadvantage to initial primary 
treatment with tamoxifen-alone although 20% of women eventually progressed to surgery.  
2.11 Other UK tamoxifen trials  
The other two UK tamoxifen trials found no differences in overall survival at a median 
follow-up of two64 or three years65.  However these trials came to different conclusions: that 
tamoxifen65 or an untested combination of mastectomy plus tamoxifen64 was the best 
option.  The Nottingham group subsequently carried out a second trial confined to patients 
who were ER-positive66.  Although this reduced tumour progression on tamoxifen-alone 
from 26% in the first trial to 3% there was no difference in overall survival compared with 
surgery alone at five years.  It should be noted that ER status was not taken into account in 
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the early trials since the test was not widely available at that time but the proportion of ER 
positive cases rises with age as does the level of oestrogen receptor expression67. 
2.12 Study 2 (Appendix 2)  
Late follow-up of a randomised trial of surgery plus tamoxifen versus 
tamoxifen alone in women over 70 with operable breast cancer. Fennessy M, 
Bates T, MacRae K, Riley D, Houghton J, Baum M.  Late follow-up of a 
randomised trial of surgery plus tamoxifen versus tamoxifen alone in women 
over 70 with operable breast cancer. Br J Surg 2004; 91: 699-704   
In view of the short three year follow-up of our CRC study it was decided to carry out a late 
review of overall survival at a median of 12.7 years68.  A final analysis was undertaken on the 
complete trial dataset where 455 patients from 27 hospitals were randomised between 
1984 and 1991. These patients were followed up for a median of 12.7 years.  As in the 
earlier analysis there was an early and marked separation of the progression-free survival 
curves with the maximum event rate now extending to the first two years of follow-up 
(Figure 2, Appendix 268).  A total of 40% patients in the tamoxifen alone group had 
subsequent surgery for local disease progression. 14 patients randomised to surgery 
rejected the allocation and received tamoxifen alone. Three patients allocated to tamoxifen 
alone elected to have surgery.  Statistical analysis was by intention to treat and not by 
treatment received. 
Survival analysis. Both the overall and cancer specific survival rates were significantly 
prolonged in the surgical group shown in Figure 3  (Figure 3, Appendix 268). The survival 
curves did not separate for the first three years, which has since led to conjecture as to the 
possible cause.  The overall mortality was increased in the tamoxifen alone group, Hazard 
ratio (HR) 1.29 (95% CI 1.04, 1.59) and in the cancer specific mortality HR 1.68 (95% CI 1.15, 
2.47).  It is possible that there may be a bias in the latter analysis since the tamoxifen alone 
group are more likely to have a residual local tumour at the time of death and to be certified 
as having died of breast cancer.  There was a clinically significant difference in 10 year 
survival rates between groups [surgery 37.7% (95% CI 31.2, 44.2) vs. tamoxifen alone 28.8% 
(95% CI 22.9, 34.8].  
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2.13 Other UK Tamoxifen trials: long-term follow-up  
The long-term results of the St George’s69 and Nottingham70 studies were subsequently 
published with a median follow-up of six and twelve years respectively. Two European RCT’s 
with long term follow-up were published in 200371,72 and although both showed an 
increased tumour progression in the tamoxifen-alone group, neither found any difference in 
overall survival at seven and ten years respectively.  The CRC study is the only RCT to show a 
significant overall survival advantage from surgery in addition to tamoxifen in this age 
group.  
2.14 Strengths of the study  
This was the first UK multicentre trial which compared tamoxifen only with tamoxifen and 
surgery. The trial was of high methodological quality whereby participants were randomised 
using a computer generated randomisation programme and allocation prior to informed 
consent and confirmation of eligibility was concealed by a central secretariat within the trial 
centre. Recruitment to the trial was good and met the required sample size. Long-term 
follow-up was conducted and provided evidence of outcome 12.7 years after 
randomisation. An additional strength was that the analysis was conducted by intention to 
treat. 
Figure 3 - Overall mortality in 455 women aged over 70 years with breast cancer 
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2.15 Weaknesses 
Participant ER status was not available even in retrospect, so that circa 10-15% of patients 
with ER negative tumours were unlikely to have benefitted from tamoxifen54. Protocol 
failure to prescribe post-operative radiotherapy for those patients who had conservative 
surgery led to a high level of local recurrence. Furthermore, there was increasing difficulty in 
achieving informed consent so that this trial did not include all eligible patients. 
2.16 Contribution to wider evidence base 
All the randomised tamoxifen trials were included within a Cochrane review and meta-
analysis73 which found that although the combination of surgery plus tamoxifen gave a 
highly significant advantage to progression-free survival, the overall survival advantage did 
not reach statistical significance [HR 0.86, 95% CI 0.73,1.00; p=0.06]. However our CRC 
Trial68 is the only RCT to demonstrate a significant overall survival benefit from surgery plus 
tamoxifen in the long term and it made a significant contribution to the conclusion of the 
meta-analysis and Cochrane review. 
The Cochrane review authors nevertheless concluded that primary endocrine therapy 
should only be offered to patients who are unfit or refuse surgery73.  [Comment: Inevitably 
this begs the question as to how fitness and refusal should best be assessed. These issues 
are subsequently considered in the Discussion.]  
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Chapter 3 – Variations in management of screen-detected breast 
cancer  
 
This chapter presents one paper on the variation in management of screen-detected breast 
cancers in women and its contribution as a fore-runner to the present national audit. Issues 
relating to screening and management of women by age are considered.  Firstly, a brief 
introduction to breast screening is presented.  
3.1 Breast Screening Programme 
The NHS breast screening programme74, introduced in 1988, was initially offered to women 
from the age of 50 to 64 and although this has been extended to age 70 and in some regions 
to age 74, older women have always been allowed to self-refer.  There has been continuing 
controversy over the NHS Breast Screening Programme fuelled by the work of Peter 
Gotzsche75 and supported by Michael Baum76.  The main criticisms of the programme are 
that the benefits from breast screening have been exaggerated and the harms of over-
diagnosis largely ignored.  This situation has been compounded by the failure of the letter of 
invitation to screening and the accompanying information leaflet to give an honest account 
of the benefits and risks of harm.  However, the public anxiety regarding the 
appropriateness of the screening programme led to the setting up of an Independent 
Review chaired by Sir Michael Marmot in 20132. 
3.2 Independent Review: The Marmot Report 
Having considered all the available evidence the Review panel found that the six evaluable 
estimates of the number of women that needed to be screened in order to save one life 
varied between 11377 and 2,00075.  The disparities depended largely on the age groups 
considered and the length of follow-up but the panel’s final conclusion lay towards the 
smaller number at 180 women that needed to be screened.  It was acknowledged that the 
risk of over-diagnosis, that a woman may be treated for an invasive or in-situ breast cancer 
that would not become apparent in her lifetime was very real and that although the 
estimate of that risk was very provisional, their best estimate was that 19% of the cancers 
diagnosed during the screening programme were over-diagnosed.  The panel concluded that 
on the balance of benefit and harm any excess mortality from over-diagnosis would be small 
and considerably outweighed by the benefits of treatment.  The screening programme 
delivers a 20% reduction in breast cancer mortality in the UK and prevents 1,300 breast 
cancer deaths a year2. 
The panel also concluded that the impact of screening outside the ages 50-69 was very 
uncertain and supported the ongoing randomised trials of inviting women aged under 50 
and over 70, although the ethics of these trials have been challenged78.  Inevitably criticism 
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has not been silenced and for older women in particular the risks of over-diagnosis would 
seem to increase with advancing years77,79-82.  On the other hand, screening young women 
who are at high risk would seem to have a sound basis83.  It is very likely that population 
screening for genetic defects will become more common but this has not so far yielded any 
major advance84. 
3.3 Study 3 (Appendix 3)  
Variations in management of small invasive breast cancers detected on 
screening in the former South Thames East Region: observational study. 
Moritz S, Bates T, Henderson S, Humphreys S, Michell MJ.  BMJ 1997; 315: 
1266-72 
Historically, patients presented to surgeons with a palpable lump in the breast but the 
screening programme diagnosed a high proportion of tumours which were impalpable. The 
practical problems which this presented only came to light with the introduction of breast 
screening.  It soon became apparent that there were considerable variations in the 
treatment of breast cancer when for the first time there was a move to record the 
treatment that each patient received in the expectation that there should be a considerable 
degree of uniformity.  One of the first hurdles to address was the ownership of the data 
which was often regarded as the personal property of individual consultant surgeons who 
were not accustomed to being audited and still less to having their judgment questioned.  
As the Surgical Coordinator for the former South East Thames Region it became apparent 
that to get the agreement of one’s surgical colleagues to release their patient data required 
some tact but also a change of culture.  This was only the start of the process to try and 
achieve some degree of uniformity in the treatment of similar patients.  
This paper reports a surgical audit of the management of patients with screen-detected 
breast cancer in the South East Region. This was one of the first regional audits to 
investigate surgical management of screen-detected breast cancers. 
3.4 Key Messages from this study: 
 In the South East Thames Region, the mastectomy rate varied between surgeons. 
Surgeons with higher caseloads tended to be more conservative, but the wide variation 
in clinical practice was not related to caseload. 
 The use of adjuvant tamoxifen in postmenopausal women with invasive breast cancer 
was high (94%) and the use of adjuvant chemotherapy low (2.5%). 
 Adjuvant radiotherapy after conservative surgery was omitted in one in five cases, but 
the omission was not related to risk factors for local recurrence. 
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 A weekly multidisciplinary meeting is an important safeguard to ensure optimal 
treatment, and any MDT should include a radiotherapist or an oncologist. (Now 
designated clinical and medical oncologist respectively).  
 When benefit has already been clearly established, treatment should be guided by 
evidence based protocols and audited by regular site visits. 
This early study addressed the variation in operation rates and adjuvant therapy in women 
with screen-detected breast cancer.  These variations subsequently became apparent with 
audits of the management of patients who presented symptomatically85.  These audits 
revealed major variations in the management of older women with symptomatic breast 
cancer which soon became apparent in screen-detected patients.  This is an on-going 
problem which is highlighted in the current audit for 2012/201386. 
These age-related and other variations continue to a lesser extent despite the constant 
attention and active intervention of an intensive and ongoing national Quality Assurance 
Reference Centres (QARC) network which was introduced with the screening programme.  
3.5 Strengths 
With the advent of the NHS Breast Screening Programme (NHSBSP) consultant breast 
surgeons were for the first time required to produce their patient data for audit. They were 
expected to meet published Guidelines for the management of screen-detected breast 
cancer. The weaknesses of some aspects of the Guidelines then current were identified, in 
particular the absence of oncologists from the multi-disciplinary team and the failure to 
recommend radiotherapy after conservative surgery. This audit highlighted seemingly 
illogical variations in clinical practice between surgeons which did not match the severity of 
casemix with the adjuvant treatment. 
3.6 Weaknesses 
The data quality was not as robust as it would be now but care was taken to ensure that 
adjuvant treatment “not given” was correct and not in fact “given but not recorded”.  This 
has been an on-going problem for the National Screening audit. Although these data had 
been presented at the annual regional breast audit meeting several surgeons complained 
that they had not given their permission or been consulted.  Note the published Conflict of 
interest. Although there is now a more general acceptance that patient care should be 
monitored and guided by a multi-disciplinary team to agreed standards rather than by an 
individual clinician, significant variations in treatment with surgery, radiotherapy and 
adjuvant hormone and chemotherapy are still not unusual at both a local and regional 
level86.   
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3.7 Overall Contribution 
What did this study add?  
This Regional audit was a forerunner of the national annual audit of the NHSBSP first 
published for 1996/1997 and presented to the Annual Meeting of the Breast Group of BASO 
(now the Association of Breast Surgery). This is now an annual event and publication; there 
are increasingly prescriptive Key Performance Indicators86. Regional Coordinators with 
responsibility for units with outlier data are publicly held to account. The publication of the 
Key Messages in the BMJ raised the profile of this study. 
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Chapter 4 - Variations in management of symptomatic breast 
cancer  
 
4.1 Study 4 (Appendix 4) 
Clinical outcome data for symptomatic breast cancer: the breast cancer 
clinical outcome measures (BCCOM) Project.  Bates T, Kearins O, Monypenny 
I, Lagord C, Lawrence G.  Br J Cancer 2009; 101(4): 395-402.  
This study85 documents the first national audit of the management of breast cancer which 
presented symptomatically (as opposed to screen-detected breast cancer).  There were 
major variations in clinical management with age and in data capture and recording by 
Regional Cancer Registries.  There were also professional problems in the validation and 
release of clinical audit data. 
4.2 Background to national data collection  
Despite the initial difficulties with data collection for screen-detected breast cancers 
referred to in Chapter 3, there was a dedicated computer programme which was funded at 
the outset by the NHSBSP in c1988 and data collection was supported by the QARCs.  
Although an annual national audit of the screening programme had become well 
established by 1998, it became increasingly apparent that it was not possible to audit the 
majority of breast cancers (80%) which were not screen-detected but mostly presented to 
general practitioners with symptoms.  There was no database on which to collect the data 
since an early database initially funded by industry collapsed.  In 2000 the Association of 
Breast Surgery (ABS) started a national data collection for symptomatic breast cancer, but 
this depended on the enthusiasm of units with good independent databases and was 
unfunded, with the result that only a third of the estimated cases were documented.   
Involvement of the Cancer Registries.  In 2003 there was a move to use the Regional Cancer 
Registries as the primary resource for symptomatic breast cancer data but it became 
apparent that written permission of individual clinicians was required for the release of 
identifiable patient data and that anonymised data might be difficult to process.  There was 
also concern that data held by some Registries might be less than complete or accurate. 
Surrogate Key Performance Indicators:  The outcome of suboptimal breast cancer treatment 
may take several years to become apparent and for this reason a series of surrogate key 
performance indicators was set up to indicate what was considered best practice by what 
became known as the Breast Cancer Clinical Outcomes Measures (BCCOM) Group.   
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Table 1  Surrogate clinical outcome measures for breast cancer proposed by 
the BCCOM Project Team 
Proposed surrogate clinical outcome measures 
1. Number and proportion of breast cancers for which complete information is received 
2. Number of symptomatic and screen-detected breast cancers treated in a hospital per annum 
3. Number and proportion of breast cancers for which there is a pre-operative diagnosis 
4. Number and proportion of breast cancers given medical treatment only 
5. Number and proportion of breast cancers treated surgically 
6. Mastectomy rate by size of breast: <15; >=15 and <=20; >20 and <=35; >35 and <=50; >50mm 
invasive diameter 
7. Number and proportion of invasive breast cancers for which nodal status is known 
8. Number and proportion of histologically node negative invasive breast cancers for which more 
than seven nodes were harvested 
9. Number and proportion of invasive breast cancers treated by breast conserving surgery and 
receiving radiotherapy 
10. Number and proportion of node positive patients with invasive breast cancers, aged 60 or 
under, receiving chemotherapy 
11. Number and proportion of patients with ER positive invasive breast cancers, receiving hormone 
therapy 
 
A breast cancer data set was designed after consultation with the ABS and the UK 
Association of Cancer Registries. The next section will discuss how the surrogate clinical 
outcome measures listed above, which were considered to represent best practice at the 
time of the study relate to the findings of the national audit of the management of breast 
cancer and its documentation.   
Surrogate Clinical Outcome Measure Nos. 1 & 2 
4.3 Separation of Screen-Detected from Symptomatic Cases 
In order to separate the screened from the symptomatic cases the Registries were asked to 
flag the screen detected cases but compliance was variable and by year three of the study, 
only 70% of screen-detected cases were identified.  The resulting contamination was only 
apparent from the higher than expected rate of non-invasive ductal carcinoma in situ (DCIS) 
- 3% for symptomatic cases and 21% for screened cases.  This was not the only difficulty in 
retrieving complete and accurate data from the Registries. 
In year 1 (2002): Registry data were sent to individual consultant surgeons for validation but 
surgical compliance to check or even to accept the data without checking was poor with the 
result that case ascertainment was far from complete. 
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In year 2 (2003): compliance with Section 60 of the Health & Social Care Act 2001 required 
writing to individual surgeons for permission to release the data to the lead breast surgeon 
in each hospital.  Predictably this further reduced the flow of data. 
In year 3 (2004): the requesting of permissions (with three exceptions) was transferred from 
the Cancer Registries to the BCCOM team at the West Midlands Cancer Intelligence Unit 
(WMCIU).  It was then possible to liaise with the ABS secretariat in order to identify 
unknown surgeons and to encourage compliance as a professional duty.  Numbers were 
reduced by the increasing exclusion of screen detected cases but the Registries gave BCCOM 
the anonymised total of all new breast cancers so that there was now a reliable 
denominator. 
4.4 Variations of Prognostic Factors and Treatment with Age 
4.4.1 Variation of Node status with Age 
Node status in patients under 50 years was recorded in 89% but in those aged over 80 this 
fell to 72%.  It was suggested that this difference was largely because the over 80’s were less 
likely to have surgery and the data would not therefore be available. [Comment: However 
there may also be an element of surgical reluctance to explore the axilla when knowledge of 
the node status may be perceived to be less important to guide subsequent adjuvant 
therapy and to indicate prognosis87.] 
Table 2 (see Appendix 6) - Variation of the Nottingham Prognostic Index88,89  
(NPI) with Age (Extrapolated from Figure 3,  Appendix 485) 
 
Nottingham Prognostic Index Group compared with Age 
NPI Group <50 50-59 60-69 70-79 80+ 
PPG (Poor) 25.5% 23.5% 22.4% 22.2% 22.4% 
EPG + GPG 
(Good/Excellent) 
22.1% 25.2% 28.2% 27.3% 28.0% 
 PPG: Poor Prognosis Group, EPG: Excellent Prognostic Group, GPG: Good Prognostic Group 
(Appendix 6) 
Interpretation: Women aged 60 and over have marginally better prognostic tumours than 
younger women. There is a possible bias in interpreting this analysis in that the higher 
proportion of unoperated cases which were excluded in women aged 8o and over may have 
excluded larger tumours.  However size has only a small effect on the NPI (Appendix 6). 
Comment: The apparent excess of Poor Prognosis Group tumours in women aged 70 or over 
with screen-detected tumours seen in Figure 3 of Appendix 485 may be explained by the 
presence of symptomatic women who are able to self-refer at this age. 
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4.4.2 Variation in Surgical Treatment with Age 
The proportion of women with breast cancer who did not receive surgery increased with 
age from 3.5% in women aged less than 50 years, to 48% in women aged 80 or more. 
 
 
The proportion of women having conservative surgery rather than a mastectomy for breast 
cancer fell from 51% in those younger than 65 years, to 42% in those aged 65 or more.  This 
variation was most marked in Wales (54% vs 26%). 
Comment: The high proportion of older women not having surgery for operable breast 
cancer has subsequently been the subject of much criticism90-92. The reduced rate of 
conservative surgery in older women may be related to the recommendation for post-
operative radiotherapy. (See below).  
Figure 4 - Variation in surgical treatment with age - year 3, 2004. (Revised from 
Figure 5  Bates et al 2009 Appendix 4)) 
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4.4.3 Variation in Adjuvant Treatment with age 
Surrogate Clinical Outcome Measure Nos. 9, 10 & 11.  
 
 
 
With increasing age, the use of adjuvant Hormone therapy gradually increased but adjuvant 
treatment with Radiotherapy and Chemotherapy rapidly declined (see below). 
 
4.4.4 Variation in Hormone Therapy with Age 
Surrogate Clinical Outcome Measure Nos. 4 & 11.  (Figure 5)   
Data on the proportion of women who received hormone therapy either as adjuvant 
therapy or as the sole primary treatment of operable breast cancer were seriously 
inadequate. Similarly knowledge of the oestrogen receptor (ER) status and the correlation 
with hormone therapy was sparse54.  Of 5,112 women who did not undergo surgery, 61% 
were recorded as receiving hormone therapy but in only 43% was the ER status known. 
Figure 5 - Variation in adjuvant Treatment with age at diagnosis, 2002-2004 
(Figure 7  Extracted from Bates et al 2009, Appendix 4)  
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Comment: The form of hormone therapy was not recorded but in 2002-2004 this is likely to 
have been tamoxifen in the majority of cases.  
4.4.5 Variation in Radiotherapy with Age 
The recorded use of radiotherapy decreased with age (Figure 5).  Of those aged under 50 
years, 78% received radiotherapy compared with only 31% of those aged over 80.  For those 
women who had conservative surgery, in those aged under 50 years 70% received post-
operative radiotherapy but this decreased to 43% in those aged 80 or above. In the three 
year period 2002-2004 radiotherapy post conservative surgery was recorded in 69% women 
but was not given in 7%. There was no record of such patients receiving post-operative 
radiotherapy in 24% cases. 
Comment: It is now well recognised that failure to give radiotherapy after conservative 
surgery leads to an unacceptably high rate of local recurrence93-95.  It is of concern that 
many older women were put at risk by this omission but also that in a quarter of cases the 
use of radiotherapy was unknown.  The high mastectomy rate in older women in Wales may 
be related to the rural population and the longer travelling times/distances to radiotherapy 
facilities which may discourage some patients, especially the elderly from having 
conservative surgery.  This rationale has been disputed but similar trends have been 
reported from rural populations in Australia96 and the Netherlands97. 
4.4.6 Variation in Chemotherapy with Age  
The proportion of women with node positive disease who had adjuvant chemotherapy, in 
those under the age of 70 was 68% but in those aged 70 or over this was only 12%. For 
those under 50 years of age c78% received chemotherapy  and Figure 5 (Figure 7 of 
Appendix 485) shows a progressive reduction in the use of chemotherapy for each age decile 
thereafter.  
Comment: The EBCCTG’s meta-analyses show a clear survival benefit from adjuvant 
chemotherapy in both node positive and negative women 98.  It is again of concern that in a 
quarter of cases this therapy is unknown or unrecorded. 
 
4.4.7 Variation in Pre-operative diagnosis*  
 Surrogate Clinical Outcome Measure No. 3 
*This is now described as non-operative diagnosis. 
A pre-operative diagnosis of invasive breast carcinoma by Fine Needle Aspiration Cytology 
or preferably by core biopsy, greatly enhances the planning of any further investigations 
such as axillary ultrasound, with or without a biopsy. Confirmation of malignancy by open 
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excisional biopsy is therefore kept to a minimum which enables the treatment options to be 
discussed with the patient before any surgery is carried out.  The guideline for a pre-
operative diagnosis of invasive breast cancers in 1998 was >70% and by 2004 was 90%.  The 
current guideline is for a minimum standard of 90% non-operative diagnosis with a Target 
Standard of 95%.  
The stated pre-operative diagnosis rate in the West Midlands was 87% but in four regions it 
was 40% or less and in Scotland only 12%.  However it seems that most Cancer Registries at 
that time only recorded the histology of resection specimens and not cytology or even core 
biopsies. 
4.4.8 Variation in Recruitment of cases with Registry and Clinical Compliance 
Wales submitted the highest proportion of eligible cases at 94% in year three (2004) but 
Thames which is the largest Registry gave only 29% cases (Table 2, Appendix 4).  In 54% 
cases the surgeon was non-compliant in submitting data on request or was unknown.  
4.4.9 Variation in Mastectomy rates by Region 
Surrogate Clinical Outcome Measure Nos. 5 & 6 
Where surgery was carried out and the details are known, the mastectomy rate for the 
whole cohort was 52.4% compared with 47.6% who had conservative surgery (Table 4, 
Appendix 4).  The proportion of women with the smallest tumours, <15mm having known 
mastectomy varied by Region from 25% in Oxford to 42% in Trent (Figure 6, Appendix 4). 
The mastectomy rates for the larger size bands are not available. Comment: The stated 
mastectomy rates for Northern Ireland, 19% and North West Region, 23% include a large 
proportion of unoperated or unknown cases.  Where the surgery was known the 
mastectomy rates were 31% and 33% respectively.   
The Erratum for Figure 6 (Appendix 4) published in Br J Cancer 2009; 101(6): 1032 refers to 
the Title of the Figure which originally stated that the data were for year three (cancers 
diagnosed in 2004).  The Corrigendum corrects the Title to state that the data apply to years 
one - three (cancers diagnosed in 2002-2004).  The data in the Figure are unchanged. 
4.4.10 Variation in Prognostic Factors and Pathology Reporting Nodal Status   
Surrogate Clinical Outcome Measure No. 7 
The overall rate of positive nodes was 32% where the denominator included unknown and 
unoperated cases.  The stated node +ve rate for operated cases was 40.5%, but if the 
unknown cases (14%) are excluded the actual rate was 47% (Table 4 / Figure 2, Appendix 4). 
The high rate of unknown data items where the patient had been operated on may be partly 
explained by the understandable reluctance of some pathologists to record the node status 
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where the patient had received preoperative neoadjuvant chemotherapy or radiotherapy.  
The concern that this might under-stage the patient is also reflected by a higher than 
expected rate of unknown values for tumour size and grade and of a calculated value for the 
NPI.  
4.5 The number of Nodes removed in a negative axillary sample – 8 or more 
nodes 
Surrogate Clinical Outcome Measure No. 8 
The number of cases in which eight or more nodes were removed from a negative axilla is 
shown in Figure 4 (Appendix 4).  In those patients who had conservative surgery this was 
found in the majority.  Following the publication of the Z 1199 and the more recent Amaros 
Trial100 it seems inevitable that practice will change with the evidence from these two 
randomised trials of node positive disease that where the tumour burden is low there is no 
advantage from radical axillary lymph node clearance.  ASCO has now published a Clinical 
Practice Guideline Update101 which states that “Women with one or two metastatic SLNs 
planning to undergo breast-conserving surgery with whole-breast radiotherapy should not 
undergo Axillary Lymph Node Dissection (ALND) (in most cases)”.   
Comment: There is increasing awareness that extensive axillary dissection leads to a high 
risk of lymphoedema102 and following the subsequent introduction of sentinel node biopsy 
(SLNB) with a much reduced number of nodes sampled from a node negative axilla, the 
incidence of lymphoedema is likely to be reduced103 although this finding has not been 
confirmed. The recently advice from ASCO is certain to accelerate change of practice and 
although the Guideline is not specific to older women it will benefit this age group as well.  
Histological type:  The data were as expected although it was noted that the incidence of 
DCIS at 5% indicated that there was still some contamination with screen detected cases.   
Tumour size:  For surgically treated cases the invasive tumour size was unrecorded in 7% 
which would be largely explained by neoadjuvant therapy.  Any association between tumour 
size and age was not stated. 
Tumour grade:  The spread of tumour grades was as expected, G1: 13%, G2: 48%, G3: 40%. 
There was a clear association between tumour size, grade and node status shown in Table 3 
(Table 4, Figure  2, Appendix 4 85)  
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Table 3 - Correlation of tumour size, grade and node status 
 
Grade 
 
1 
 
2 
 
3 
 
Nodes Positive 
 
29% 
 
47% 
 
54% 
 
Size >5cm 
 
3% 
 
8% 
 
10% 
Any association between tumour grade and age was not stated. 
4.6 Completeness of Regional Records 
Surrogate Clinical Outcome Measure Nos. 1 & 2   
The shortfall in data collection, or those data which were retrievable, has been highlighted 
in each section of this audit.  The  main shortfall has been the amount and accuracy of data 
items held by individual Cancer Registries of which the Thames Region was the largest and 
most conspicuous outlier (Table 2, Appendix 485).   The use of surrogate measures to reflect 
compliance with best practice produced valuable data on current practice with the 
exception of Measures 1 & 2 where the requirement for written permission for the release 
of individual patient data severely restricted access to data.  However much of the shortfall 
of data stemmed from the reluctance of some surgeons to verify the data held on their 
patients.  
The voluntary release of data “has been a prerequisite of the BCCOM audit to date, (and) it 
seems clear that the collection of cases will not approach completeness on this basis”. 
Comment: The recent government requirement that the results of individual surgeons 
should be published and the need to document clinical practice for annual appraisal and 
subsequent revalidation has transformed the situation.  However the management of an 
individual patient with breast cancer often involves care given by several professionals and 
sometimes by more than one surgeon.  
4.7 Variation in the management of Breast cancer in the UK 
There are still major variations in the management of breast cancer in the UK104 which may 
also affect outcome; variations in mastectomy rates, in the use of adjuvant therapy and with 
the management of older patients.  Such variations colloquially known as a “Postcode 
Lottery” may affect the management of breast cancer at every point in the patient’s journey 
and have sometimes depended upon the decision of a clinician, which may be idiosyncratic 
rather than evidence based.  
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4.8 Strengths 
This audit documented for the first time the extent and shortfall of retrievable data on the 
management of symptomatic breast cancer from Regional Cancer Registries in the UK in 
2002-2004. It also documents the extent of the reluctance of surgeons to validate and 
release data for audit on patients under their care. The audit set up a series of surrogate 
measures to reflect best practice at the time. Having indicated the expected surrogate 
outcome measures the audit was able to document variations from best practice. 
4.9 Weaknesses 
The surrogate measures did not include important criteria for best practice for which data 
were not available at that time e.g. reconstruction post-mastectomy, quality of life 
measures and patient reported outcome measures (PROMS). The large proportion of 
unrecorded data items retrievable from most UK Cancer Registries. Finally, another 
weakness is the lack of any statistical analysis. 
4.10 Overall Contribution 
Key messages for Chapter 4:-  
 First UK national audit of surgical practice for symptomatic breast cancer. 
 Overall findings included identification of variation in surgical participation for the 
release of data by UK region from 29% to 94%.  
 Poor quality data reporting includes the challenge of missing data. 
 Variation by age:  
o Reduced surgical treatment.  
o Reduced use of adjuvant therapy.  
o Reduced identification of axillary node status.  
o National study identified major regional differences in treatment by age.  
This was a wake-up call to the Cancer Registries and the breast surgical community to agree 
a common process and to improve overall reporting and data quality. It was acknowledged 
that patient data does not belong to an individual surgeon and that there is a professional 
responsibility that this should be validated and be made available for audit and research 
within appropriate safeguards. Finally, this was the forerunner to the regular National audit 
of symptomatic breast cancer. 
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Chapter 5 - Variation in Operation Rates for Breast Cancer with Age, 
Comorbidity, Ethnicity, Socio-economic status, Screening status and 
Prognostic Factors 
 
5.1 Study 5 (Appendix 5) 
A Population based study of variations in operation rates for breast cancer, 
of comorbidity and prognosis at diagnosis: Failure to operate for early breast 
cancer in older women. Bates T, Evans T, Lagord C, Monypenny I, Kearins O, 
Lawrence G.   Eur J Surg Oncol. 2014; 40: 1230-1236.   
This study21 expanded on the 2007 data published in the Second All Breast Cancer Report105, 
in particular it evaluated comorbidity data using Hospital Episode Statistics (HES) data for 
England.  Cancer statistics for England are now reported separately since the other countries 
in the UK capture and report social deprivation status using different methods.  At this time, 
comorbidity data were only available for England.  
5.2 Comorbidity Assessment Scales 
There are several assessment scales of comorbidity which have been reviewed by Stotter106 
who, having trialled the Satariano Index107, settled on the validated Charlson Comorbidity 
Index (CCI)108.  The CCI has been criticised as being potentially biased towards cancer 
comorbidity109 and for this reason all cancer diagnoses were removed from the modified 
version110 in the current study.  There are several population studies of comorbidity with 
age and these suggest that even where it was possible to calculate the CCI in the very 
elderly, that the HES data under-record the true incidence of comorbidity 111-113.  The CCI 
was not available for 9% of those under the age of 80 but in those aged 80 or over there was 
no HES record in 22% which will largely include those who were not operated on and had 
not therefore had a hospital admission.  It seems very probable that this group will have had 
a higher degree of comorbidity.  
5.3 Variation in Operation Rates with Comorbidities 
Variation in operation rates and in comorbidities with age are shown in Table 4 and Figure 6 
(Figure 1, Appendix 521) and in the Supplementary Data (Table 421 ).  
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Modified CCI comorbidity scores were scored 1,2,3 and 6 depending on risk from 
death110.  The comorbidity values were obtained from HES data for each patient based upon 
the previous 18 months of hospital admissions prior to cancer diagnosis, up to and including 
the date of diagnosis. The score reflects a sum of each comorbidity score diagnosed.  
5.4 Failure to operate 
Variation with age: the proportion of women aged 35 or over not having surgery for breast 
cancer up to the age of 70 varied between 7% & 10% but thereafter rose steadily by 3.1% 
per year of age to reach 82% in those aged 90 or over: Figure 6 (Figure 2, Appendix 521). 
  
Table 4 - Supplementary Data: Correlation between Charlson Comorbidity Index 
(CCI) and No Surgical Treatment 
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Figure 6 - Variation in operation rates for breast cancer with age and the 
proportion of women with a Charlson Comorbidity Index (CCI) of 2 or more 
 
 
The factors which affect the likelihood of not having a surgical operation for breast cancer 
are shown in Figure 7 (Figure 2, Appendix 521) 
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Figure 7 - Factors associated with not having a breast cancer operation (odds 
ratio, 95% CI) 
 
 
The likelihood of not having an operation rose progressively with an increasing CCI score.  
The odds ratios taken from Figure 7 are for a CCI score of 1: OR 1.28 (95% CI 1.11, 1.48), CCI 
2: OR 2.53 (95% CI 2.05, 3.11), CCI 3: OR 3.63 (95% CI 2.57, 5.14) and for CCI 4+: OR 7.6 (95% 
CI 4.79, 12.05) 
 
5.5 Variation with Ethnicity 
Women of all non-white ethnic groups were more likely to present with poor prognosis PPG 
breast cancer (Table 3, Appendix 521) and women of Asian or black ethnicity were less likely 
to present with tumours of good prognosis EXG/GPG or small tumours (Tables 1&2, 
Appendix 521).  This finding is not unexpected especially with respect to black women, OR 
0.36 (95% CI 0.25, 0.53) p<0.00122,114,115.  However black women were more likely to have 
had an operation in the present study: Figure 7 (Figure 2, Appendix 521).  Ethnic differences 
in survival are confounded but not wholly explained by socio-economic status23,116. 
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5.6 Variation with Socio-economic status 
As expected, women from the more and most deprived cohorts were less likely to present 
with a good prognosis breast cancer (Table 1, Appendix 521) and the most deprived were 
less likely to have small tumours (Table 2, Appendix 521).  However there was no variation in 
operation rates by socio-economic status shown in Figure 7 (Figure 2, Appendix 521).  The 
American Surveillance, Epidemiology and End Results (SEER) data up to 2005 do not suggest 
failure to operate for breast cancer due to socio-economic/ethnic factors, but failure to give 
radiotherapy after conservative surgery is clear94,95. 
5.7 Variation with Screen Detected cases 
As expected the screen detected cases were more likely to have presented with uniformly 
favourable features; good prognosis tumours: OR 4.78 (95% CI 4.43, 5.16), small tumours: 
OR 3.96 (95% CI 3.69, 4.24), and less likely to have poor prognosis tumour: OR 0.2 (95% CI 
0.18, 0.22) and less likely to not have an operation: OR 0.61 (95% CI 0.45, 0.83). 
5.8 Prognosis 
Although we have used the extremes of the Nottingham Prognostic Index (NPI) as two of 
the four criteria to indicate a good or a poor prognosis it should be appreciated that the NPI 
has not been validated for women aged over 70 in either the UK cohort117 or the extensive 
European Oncopool Study118 since Blamey excluded this age group “because treatment was 
not always operative, axillary status was not established in all, adjuvant systemic therapies 
were frequently not applied and to avoid the confounding factor of high mortality from 
causes other than breast cancer”. 
In considering prognosis, Voogd et al119 point out that international  comparisons of cancer 
survival such as the EUROCARE studies may be confounded by variations in the proportion 
of death certificate only (DCO) registrations, where there has been a prior failure of case 
ascertainment.  The Thames Region reported 24% of cancer cases as DCOs in 1987-1989 
which were positively associated with increasing age120.  Although this rate subsequently 
improved the high rate of DCO cases was initially responsible for a significant difference in 
unadjusted survival rates compared with the Finnish Cancer Registries data which were 
largely complete121. 
5.9 Variation with Prognostic Factors 
Variation with tumour size:  women with tumours greater than 5cm in diameter were less 
likely to have an operation, as were those where the tumour size was unknown – because 
the tumour was un-operated. Variation with tumour grade and node status: women with 
tumours of grade 2 versus grade 1 were less likely to have an operation as were those who 
were node positive versus node negative.  As with tumour size, surgery was unlikely where 
the grade or node status was unknown. 
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5.10 Discussion 
The current NICE Guidance (2009) recommends that clinicians treat patients with early 
invasive breast cancer, irrespective of age, with surgery and appropriate systemic therapy 
rather than endocrine therapy alone, unless significant morbidity precludes surgery122.  
However there are many reports which document the reduced rate of surgical treatment for 
breast cancer with advancing age but the extent to which this is related to increasing 
comorbidity is considered in the Discussion21, pp 1132s-5 and in a review of 18 international 
studies123.  There can be no doubt that increasing levels of comorbidity reduce non-cancer 
and overall survival124-129 but where there is a reduction of cancer-specific survival this may 
be related to reduced treatment130,131. The question arises as to whether failure to operate 
is always a real failure or whether this sometimes reflects the patient’s well-informed 
choice? There is a wealth of literature that documents reducing operation rates for operable 
breast cancer with advancing age with the presumption that patients are being denied 
optimal treatment on the basis of surgical prejudice90-92,132,133  and with the 
recommendation that more appropriate preoperative assessment will lead to better 
treatment of the elderly134-138.  On the other hand there are those who express doubts as to 
whether the elderly are significantly disadvantaged by perceived under-treatment139-141.  
The literature on patient choice as a cause for variation in operation rates in older women is 
relatively sparse and not conclusive.  In a review of patients’ records Lavelle et al. concluded 
that poor health or patient choice did not wholly account for the lack of surgery in patients 
aged over 85142.  However others have found in the over 80’s that patient choice accounted 
for a third of those who did not have surgery for operable breast cancer92,143.  In a cohort of 
older patients with breast cancer, of those who did not have surgery Tang et al commented, 
“when offered a genuine choice....most patients chose non-operative treatment”144.  In a 
study of an MDT for breast cancer patients, 4.5% did not receive the treatment 
recommended, of which patient choice was the most common factor and accounted for 
42% of discordant treatments145.  
In an audit of a dedicated Multidisciplinary Elderly Breast Cancer Clinic, as to why under-
treatment of the elderly with breast cancer was so common, Stotter106  found that the 
patient’s “frailty was overestimated …… (and their) life expectancy was underestimated”.  
However she acknowledged that the discussion with the patient can be a very slow process 
and that support of the accompanying person can sometimes create a problem in failing to 
recognise the patient’s wishes and priorities. 
The report by the Royal College of Surgeons England, “Access all ages: Assessing the impact 
of age on access to surgical treatment”146 spells out the constraints  imposed by the Equality 
Act 2010, which bans age discrimination without strong clinical evidence to justify this.  
However as well as operation rates by age for breast cancer the examples from a raft of 
common operations show little difference. The rates for surgery by age for each of these 
operations show a peak between 70 and 80 and a precipitous decline thereafter.  The 
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Report recommends a geriatric input to MDT’s but this would not seem to be a realistic 
expectation in the near future.  Schonberg et al147 found that most women over 75 just 
followed the surgeon’s recommendation which was the most influential factor affecting 
their treatment decision. The breast clinician therefore has a considerable responsibility for 
giving the older woman a balanced view132, allowing time for her to make a decision and 
using a basic geriatric screening instrument138 where appropriate. 
5.11 Personal perspective 
I feel that consent to treatment of breast cancer should be a process rather than a one-off 
event and the breast specialist nurse is often an important intermediary in enabling the 
patient to reach a decision having considered all the reasonable options.  The opinion of the 
multidisciplinary meeting is very important but in the setting of this age group it should 
ideally be couched in terms of treatment options, albeit with prioritisation rather than as a 
directive.  A Comprehensive Geriatric Assessment should be available when this is 
appropriate but this will not always be the case in many smaller units.  I would  agree with 
the position of the Cochrane Review73,148 and the current NICE Guidance122 which conclude 
that that surgery for the elderly with ER positive breast cancer gives better local control and 
that primary endocrine therapy should be reserved for patients with significant comorbid 
disease or who refuse surgery.  I would only rephrase the final conclusion – or those who 
have decided not to have an operation. 
5.12 Strengths 
 The failure to operate on older women with apparently operable breast cancer to some 
extent relates to increasing comorbidity in this age group. 
 The confounding factors of variations in prognosis and treatment related to socio-
economic status, ethnicity, geographical region and breast screening are confirmed. 
 By using all available sources the data are more robust than the BCCOM dataset 2004. 
5.13 Weaknesses 
 HES Comorbidity data were only available for England. 
 HES data are only available for women who have had a hospital admission.  In 
consequence there are no comorbidity data available for most of the women who were 
not operated on. 
 HES data probably under-record the likely number of comorbidities in older women. 
 The extent to which patient choice affects the treatment of breast cancer in older 
women is unresolved. 
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5.14 Overall contribution 
This study documents the incidence of comorbidity of older women with breast cancer, 
albeit this may be under-recorded or unavailable in those women who were not operated 
on. The steady rise in the non-operative treatment of breast cancer at 3.1% per year of age 
from age 70 has not previously been noted. The quality of data from the National Cancer 
Registration Database has substantially improved on that available to BCCOM for 2002-
2004. Finally, the weakness of HES data on comorbidity has been highlighted. 
 
I submit that this body of published work comprises a coherent theme, which examines 
many of the factors which lead to variation in the management of older patients presenting 
with potentially operable breast cancer.  
 
 
Tom Bates 
 
Word count: 9,954. 
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Appendix 1   Study 1 
Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment 
with tamoxifen and optimal surgery with tamoxifen alone61. 
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Appendix 2  Study 2 
Late follow-up of a randomised trial of surgery plus tamoxifen versus tamoxifen alone in 
women over 70 with operable breast cancer68. 
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Appendix 3 Study 3 
Variations in management of small screen-detected breast cancer in the South Thames East 
Region104. 
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Appendix 4 Study 4 
Clinical outcome data for symptomatic breast cancer: the breast cancer clinical outcome 
measures (BCCOM) Project85. 
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Appendix 5 Study 5   
A Population Based Study of Variations in Operation Rates for Breast Cancer, of Comorbidity 
and Prognosis at Diagnosis: Failure to Operate for Early Breast Cancer in Older Women21. 
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Appendix 6 - Nottingham Prognostic Index88,89 (NPI)  
  
Nottingham Prognostic Index: Definitions 
 
NPI = Grade + Nodes + Size (cm) x 0.2 
 
Nodes Positive:  Nil  = 1 1-3 +ve = 2  ≥4 +ve = 3 
 
  Excellent Prognostic Group 
 
EPG 
 
≤2.4 
 
  Good Prognostic Group 
 
GPG 
 
>2.4 – 3.4 
 
  Moderate Prognostic Group 1 
 
MPG1 
 
>3.4 - 4.4 
 
  Moderate Prognostic Group 2 
 
MPG2 
 
>4.4 - 5.4 
 
  Poor Prognostic Group 
 
PPG 
 
>5.4 
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Appendix 8   Signed Statements of candidate’s contribution 
The individual signatures of the 15 co-authors who are still alive have been scanned and 
inserted below. Original copies and scans of signed Statement of Contribution documents 
are held on file by the University of Warwick.  
Paper to be considered as part of the PhD by Published Work (1)  
1. Bates T, Riley DL, Houghton J, Fallowfield L, Baum M.  Breast cancer in elderly women: a 
Cancer Research Campaign trial comparing treatment with tamoxifen and optimal 
surgery with tamoxifen alone.   Br J Surg 1991; 78: 591-4. 
Study circumstances:  
In the setting of uncertainty on the use of tamoxifen as a sole primary treatment for 
operable breast cancer in older women, 3 RCTs were set up in the 1980s in the UK, at St 
George’s, at Nottingham and the present multicentre Cancer Research Campaign (CRC) 
study centred at King’s. The trials at Nottingham and St George’s both compared surgery 
alone with Tamoxifen alone but it was felt that there was an ethical difficulty in withholding 
tamoxifen from one group of patients in view of the mounting evidence of benefit from 
primary endocrine therapy. As principal investigator and in collaboration with Michael Baum 
at the CRC Unit, I therefore set up a multicentre RCT to compare Tamoxifen alone with 
Tamoxifen together with optimal surgery in women over the age of 70 with operable 
primary breast cancer.  
Contribution of candidate: Tom Bates took a lead role as principal investigator in the 
design, conduct and evaluation of this RCT in collaboration with Professor Baum and the 
CRC Unit at Kings.  He wrote the manuscript in liaison with the co-authors and responded to 
reviewers as the corresponding author. 
I agree that Tom Bates made the aforementioned contribution to this publication. 
Name    Signature    Date 
Di Riley 
Joan Houghton 
Lesley Fallowfield 
Michael Baum   
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Paper to be considered as part of the PhD by Published Work (2)  
2. Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M.  Late follow-up of a 
randomised trial of surgery plus tamoxifen versus tamoxifen alone in women over 70 
with operable breast cancer. Br J Surg 2004; 91: 699-704. 
 
Study circumstances:  
In view of the short three year follow-up of our CRC study it was decided to carry out a late 
review of overall survival at a median of 12.7 years. A final analysis was undertaken on the 
455 patients from 27 hospitals who were randomised between 1984 and 1991. As in the 
earlier analysis there was an early and marked separation of the progression-free survival 
curves with the maximum event rate now extending to the first two years of follow-up. 
Statistical analysis was by intention to treat and both overall and cancer specific survival 
rates were now significantly prolonged in the surgical group of patients. In a subsequent 
Cochrane review and meta-analysis surgery plus Tamoxifen gave a highly significant 
advantage to progression-free survival, but overall survival advantage did not reach 
statistical significance. This CRC Trial is the only RCT to demonstrate a significant overall 
survival benefit from surgery plus Tamoxifen in the long term. 
Contribution of candidate: Tom Bates in collaboration with Professor Baum decided that a 
long-term follow-up of this trial was important and Michael Fennessy accessed and analysed 
the archival data. Tom Bates wrote the manuscript in liaison with the co-authors and 
responded to reviewers as the corresponding author. 
I agree that Tom Bates made the aforementioned contribution to this publication. 
Name     Signature    Date 
Michael Fennessy   Unavailable  
Di Riley 
Joan Houghton 
Michael Baum  
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Paper to be considered as part of the PhD by Published Work (3) 
3. Moritz S, Bates T, Henderson S, Humphreys S, Michell MJ.  Variations in management of 
small invasive breast cancers detected on screening in the former South Thames East 
Region: observational study.  BMJ 1997; 315: 1266-72 
Study circumstances: 
With the introduction of the breast screening programme (BSP) it soon became apparent 
that there were considerable variations in the treatment of breast cancer and one of the 
first hurdles to address was the ownership of the data.  To get the agreement of one’s 
surgical colleagues to release their patient data required some tact but also a change of 
culture.  This paper reports one of the first surgical audits of the management of patients 
with screen-detected breast cancer. The Key Messages included: in the South East Thames 
Region, the mastectomy rate varied between surgeons.  Those with higher caseloads tended 
to be more conservative, but the wide variation in clinical practice was not related to 
caseload. When benefit has already been clearly established, treatment should be guided by 
evidence based protocols and audited by regular site visits. 
Contribution of candidate:  As the Surgical Coordinator for the Region Tom Bates was 
responsible for the surgical aspects of the BSP and audited the process. Sabina Moritz 
collected and collated the data.  TB wrote the manuscript in liaison with the co-authors and 
responded to reviewers as the corresponding author. 
I agree that Tom Bates made the aforementioned contribution to this publication. 
Name         
Sabina Moritz 
Sue Henderson 
Steve Humphreys   Unavailable  
Michael Michell 
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Paper to be considered as part of the PhD by Published Work (4)  
4. Bates T, Kearins O, Monypenny I, Lagord C, Lawrence G.  Clinical outcome data for 
symptomatic breast cancer: the breast cancer clinical outcome measures (BCCOM) 
project.  Br J Cancer 2009; 101(3): 395-402  
Study circumstances: 
Although an annual national audit of the screening programme had become well 
established by 1998, it became increasingly apparent that it was not possible to audit the 
majority of breast cancers (80%) which were not screen-detected but mostly presented to 
general practitioners with symptoms.  This study documented the first national audit of the 
management of Breast Cancer which presented symptomatically. The outcome of 
suboptimal breast cancer treatment may take several years to become apparent and for this 
reason a series of surrogate key performance indicators (KPI) was set up to indicate what 
was considered best practice.  There were major variations in clinical management with age 
and in data capture and recording by Regional Cancer Registries. There were also 
professional problems in the validation and release of clinical audit data. 
Contribution of candidate:  The need for this audit was identified by Ian Monypenny, Tom 
Bates and Gill Lawrence and they drew up the surrogate KPI’s.  The data were collected and 
analysed by Olive Kearins, Catherine Lagord and Gill Lawrence.  TB checked the data and 
wrote the manuscript in liaison with the co-authors. 
I agree that Tom Bates made the aforementioned contribution to this publication. 
Name                                                             Signature                                                      Date 
Olive Kearins 
Ian Monypenny 
Catherine Lagord 
Gill Lawrence 
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Paper to be considered as part of the PhD by Published Work (5)  
5. Bates T, Evans T, Lagord C, Monypenny I, Kearins O, Lawrence G.  A population based 
study of variations in operation rates for breast cancer, of comorbidity and prognosis at 
diagnosis: Failure to operate for early breast cancer in older women.  Eur J Surg Oncol 
2014; 40(10): 1230-6.  
Study circumstances: 
This study expanded on the 2007 data published in the Second All Breast Cancer Report and 
evaluated comorbidity data using Hospital Episode Statistics (HES) data for England.  At this 
time, comorbidity data were only available for England. The Charlson Comorbidity index 
(CCI) was calculated removing all cancer comorbidities.  It was not possible to calculate the 
CCI in most women who did not have surgery and therefore no HES data .Failure to operate 
for breast cancer rose by 3.6% per year of age, from age 70. 
Contribution of candidate:    The data were collected by Olive Kearins, Catherine Lagord and 
Gill Lawrence. The data were analysed by Tim Evans who calculated the CCI values. TB 
checked the data and wrote the manuscript in liaison with the co-authors and responded to 
reviewers as the corresponding author. 
I agree that Tom Bates made the aforementioned contribution to this publication. 
Name                                                             Signature                                                      Date 
Tim Evans 
Olive Kearins 
Ian Monypenny 
Catherine Lagord 
Gill Lawrence 
 
 
